FAQ

CCT 137690

Known as: CCT-137690, CCT137690 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2017
0120102017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
BACKGROUND & AIMS Induction of nonapoptotic cell death could be an approach to eliminate apoptosis-resistant tumors. We… (More)
Is this relevant?
2014
2014
Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy
Colorectal cancer is the third most commonly diagnosed cancer worldwide. Although surgery remains the best treatment for this… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2013
Review
2013
Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Acute myelogenous leukemia (AML) can progress quickly and without treatment can become fatal in a short period of time. However… (More)
  • table 1
Is this relevant?
2012
2012
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
Acquired resistance to selective FLT3 inhibitors is an emerging clinical problem in the treatment of FLT3-ITD+ acute myeloid… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Aurora kinases regulate key stages of mitosis including centrosome maturation, spindle assembly, chromosome segregation, and… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2011
2011
Preclinical Development The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo
Aurora kinases regulate key stages of mitosis including centrosome maturation, spindle assembly, chromosome segregation, and… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2010
2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.
Lead optimization studies using 7 as the starting point led to a new class of imidazo[4,5-b]pyridine-based inhibitors of Aurora… (More)
Is this relevant?